Background: Ovarian cancer is tagged as deadly condition worldwide. The delay in diagnosis due to late presentation and lack of specific screening tests. HE4 and CA15-3 are considered as noninvasive marker with varied cut off reference and sensitivity, specificity among various populations. Objective: The objective of this study was to investigate correlation along with sensitivity, specificity, PPV, NPV of HE4, CA15-3 and CA125 among epithelial ovarian cancer. Methods: This cross section comparative study was conducted on 70 diagnosed ovarian cancer cases age (20 to ≥70) year of any FIGO stage (I-IV after approval from IRB and ethical review board (UHS/Reg-17/ERC-4659) of University of Health sciences. The blood samples were taken and serum levels of HE4 and CA15-3 were measured by ELISA. While CA125 was determined from patient investigation reports. Results: This study found positive correlation (r=0.089 p=0.66) between malignant and borderline ovarian tumors for HE4, while negative correlation between early (I and II) and advanced (stage III and IV) FIGO stage with r=-0.028 p=0.876. Whereas, for CA15-3 negative correlation was observed with r= -0.006 p=0.980 between malignant and borderline variants of epithelial ovarian cancer and also negative correlation was seen between early (I and II) and advanced (stage III and IV) FIGO stage with r= -0.095 p=0.588. Conclusions: The discriminative strength of HE4 as biomarker determined by ROC curve was 0.55%. Hence HE4 can be used for diagnosis or prognosis of ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: